At-Home Care for Acute Myeloid Leukemia Patients on Venetoclax
Author Information
Author(s): Martínez-Roca Alexandra, Jiménez-Vicente Carlos, Merchán Beatriz, Castaño-Diez Sandra, Zugasti Inés, Brillembourg Helena, Bataller Álex, Guijarro Francesca, Cortés-Bullich Albert, Trigueros Ana, Pérez-Valencia Amanda Isabel, Gallego Cristina, Ballestar Nuria, Rodríguez-Lobato Luis Gerardo, Carcelero Esther, Díaz-Beyá Marina, Esteve Jordi, Fernández-Avilés Francesc, Robak Tadeusz
Primary Institution: Hospital Clínic Barcelona
Hypothesis
Can an At-Home (AH) program improve outcomes for patients with acute myeloid leukemia (AML) treated with venetoclax-based regimens?
Conclusion
The At-Home management program was safe and effective, leading to lower hospital readmission rates and improved patient well-being.
Supporting Evidence
- Patients in the AH cohort had a significantly lower hospital readmission rate after ramp-up (29.5% vs. 84.6%).
- The AH cohort had shorter hospital stays compared to the inpatient cohort (8 vs. 13 days).
- 96.9% of patients experienced grade 3–4 cytopenia, but serious infections were similar between groups.
- The AH program allowed for continuous patient follow-up and education, improving treatment compliance.
- No cases of tumor lysis syndrome were observed in either group.
- Patients in the AH program reported better comfort and well-being.
Takeaway
This study shows that patients with leukemia can be treated at home safely, which helps them feel better and stay out of the hospital.
Methodology
A retrospective analysis comparing outcomes of patients treated with venetoclax and azacitidine in a hospital setting versus an At-Home program.
Potential Biases
Potential selection bias in patient inclusion for the AH program.
Limitations
The study is retrospective and conducted at a single center, which may limit generalizability.
Participant Demographics
Patients included were adults over 18 years, with a median age of 71 years, mostly diagnosed with adverse risk AML.
Statistical Information
P-Value
0.0001
Confidence Interval
95% CI 10.3–NA for ND-AML patients; 95% CI 4.97–9.44 for R/R AML patients
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website